Mabwell (Shanghai) Bioscience (688062) Stock Overview
A biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
688062 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Mabwell (Shanghai) Bioscience Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.52 |
| 52 Week High | CN¥63.59 |
| 52 Week Low | CN¥25.13 |
| Beta | 0.53 |
| 1 Month Change | 27.71% |
| 3 Month Change | -10.96% |
| 1 Year Change | -7.53% |
| 3 Year Change | 65.25% |
| 5 Year Change | n/a |
| Change since IPO | 40.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688062 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 11.2% | 8.1% | -1.5% |
| 1Y | -7.5% | -18.3% | 19.0% |
Return vs Industry: 688062 exceeded the CN Biotechs industry which returned -18.3% over the past year.
Return vs Market: 688062 underperformed the CN Market which returned 19% over the past year.
Price Volatility
| 688062 volatility | |
|---|---|
| 688062 Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in CN Market | 11.6% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 688062 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688062's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 1,325 | Datao Liu | www.mabwell.com |
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17.
Mabwell (Shanghai) Bioscience Co., Ltd. Fundamentals Summary
| 688062 fundamental statistics | |
|---|---|
| Market cap | CN¥14.76b |
| Earnings (TTM) | -CN¥919.55m |
| Revenue (TTM) | CN¥745.32m |
Is 688062 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688062 income statement (TTM) | |
|---|---|
| Revenue | CN¥745.32m |
| Cost of Revenue | CN¥96.18m |
| Gross Profit | CN¥649.14m |
| Other Expenses | CN¥1.57b |
| Earnings | -CN¥919.55m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 31, 2026
| Earnings per share (EPS) | -2.06 |
| Gross Margin | 87.09% |
| Net Profit Margin | -123.38% |
| Debt/Equity Ratio | 1,075.3% |
How did 688062 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/16 17:00 |
| End of Day Share Price | 2026/07/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mabwell (Shanghai) Bioscience Co., Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| David Dong | CLSA |
| Yiling Chen | Guosen Securities Co., Ltd. |